Skip to main content


Page 3 of 18

  1. Approximately 400,000 people who smoke cigarettes survive Acute Coronary Syndrome (ACS; unstable angina, ST and non-ST elevation myocardial infarction) each year in the US. Continued smoking following ACS is a...

    Authors: Melissa Adkins-Hempel, Sandra J. Japuntich, Michelle Chrastek, Shira Dunsiger, Christopher E. Breault, Woubeshet Ayenew, Susan A. Everson-Rose, Prabhjot S. Nijjar, Beth C. Bock, Wen-Chih Wu, Michael D. Miedema, Brett M. Carlson and Andrew M. Busch
    Citation: Addiction Science & Clinical Practice 2023 18:29
  2. Although the detrimental health effects of alcohol are well established, consumption levels are high in many high-income countries such as Germany. Improving alcohol health literacy presents an integrated appr...

    Authors: Jakob Manthey, Daša Kokole, Steffi Riedel-Heller, Gill Rowlands, Ingo Schäfer, Georg Schomerus, Renate Soellner and Carolin Kilian
    Citation: Addiction Science & Clinical Practice 2023 18:28
  3. Alcohol use disorders (AUD) are prevalent and often go untreated. Patients are commonly screened for AUD in primary care, but existing treatment programs are failing to meet demand. Digital therapeutics includ...

    Authors: Jessica M. Mogk, Theresa E. Matson, Ryan M. Caldeiro, Angela M. Garza Mcwethy, Tara Beatty, Brandie C. Sevey, Clarissa W. Hsu and Joseph E. Glass
    Citation: Addiction Science & Clinical Practice 2023 18:27
  4. Most people with opioid use disorder (OUD) have co-occurring substance use, which is associated with lower receipt of OUD medications (MOUD). Expanding MOUD provision and care linkage outside of substance use ...

    Authors: Madeline C. Frost, Elena M. Soyer, Carol E. Achtmeyer, Eric J. Hawkins, Joseph E. Glass, Kevin A. Hallgren and Emily C. Williams
    Citation: Addiction Science & Clinical Practice 2023 18:26
  5. Individuals with substance use disorder (SUD) have high prevalence of cigarette smoking and difficulty quitting. Peer recovery coaches (PRCs; individuals with lived SUD experience) facilitate SUD behavior chan...

    Authors: Joanna M. Streck, Susan Regan, Michael Werner, Alexia Glynn, Andrea C. Villanti, Elyse R. Park, Sarah E. Wakeman, A. Eden Evins and Nancy A. Rigotti
    Citation: Addiction Science & Clinical Practice 2023 18:25
  6. National opioid-related overdose fatalities totaled 650,000 from 1999 to 2021. Some of the highest rates occurred in New Hampshire, where 40% of the population lives rurally. Medications for opioid use disorde...

    Authors: Owen B. Murray, Marcy Doyle, Bethany M. McLeman, Lisa A. Marsch, Elizabeth C. Saunders, Katherine M. Cox, Delitha Watts and Jeanne Ryer
    Citation: Addiction Science & Clinical Practice 2023 18:24
  7. The opioid overdose and polysubstance use crises have led to the development of low-barrier, transitional substance use disorder (SUD) treatment models, including bridge clinics. Bridge clinics offer immediate...

    Authors: Jessica L. Taylor, Sarah E. Wakeman, Alexander Y. Walley and Laura G. Kehoe
    Citation: Addiction Science & Clinical Practice 2023 18:23
  8. Attempts to routinely embed brief interventions in health systems have long been challenging, with healthcare professionals concerned about role adequacy, legitimacy, and support. This is the first study to ex...

    Authors: Mary Madden, Duncan Stewart, Thomas Mills and Jim McCambridge
    Citation: Addiction Science & Clinical Practice 2023 18:22
  9. Federal and state regulations require frequent direct observation of methadone ingestion at an Opioid Treatment Program (OTP)—a requirement that creates barriers to patient access. Video observed therapy (VOT)...

    Authors: James B. Darnton, Elenore P. Bhatraju, Kristin Beima-Sofie, Alyssa Michaels, Kevin A. Hallgren, Sean Soth, Paul Grekin, Steve Woolworth and Judith I. Tsui
    Citation: Addiction Science & Clinical Practice 2023 18:21
  10. Medications for opioid use disorder (MOUD) are associated with positive health outcomes. People remaining on MOUD have a reduced likelihood of drug overdose and mortality. Tanzania supports a national opioid t...

    Authors: Deja Knight, Iddi Haruna Nkya, Nora Solon West, Cui Yang, Michael Kidorf, Carl Latkin and Haneefa T. Saleem
    Citation: Addiction Science & Clinical Practice 2023 18:19
  11. Despite the frequent comorbidity of substance use disorders (SUDs) and psychiatric disorders, it remains unclear if screening for substance use in behavioral health clinics is a common practice. The aim of thi...

    Authors: Diana Woodward, Timothy E. Wilens, Meyer Glantz, Vinod Rao, Colin Burke and Amy M. Yule
    Citation: Addiction Science & Clinical Practice 2023 18:18
  12. Alcohol and cannabis are the most commonly used substances among adolescents in the U.S. The consequences related to using both substances together are significantly higher relative to use of either substance ...

    Authors: Karen Chan Osilla, Elizabeth J. D’Amico, Rosanna Smart, Anthony Rodriguez, Katherine Nameth and Justin Hummer
    Citation: Addiction Science & Clinical Practice 2023 18:17
  13. During the period of community re-entry immediately following release from jail or prison, individuals with opioid use disorder (OUD) face structural barriers to successful re-entry and high risk of overdose. ...

    Authors: Kim A. Hoffman, Emma Thompson, Marina Gaeta Gazzola, Lindsay M. S. Oberleitner, Anthony Eller, Lynn M. Madden, Ruthanne Marcus, David E. Oberleitner, Mark Beitel and Declan T. Barry
    Citation: Addiction Science & Clinical Practice 2023 18:16
  14. Heroin-assisted treatment (HAT) is a proven effective treatment option for individuals with severe opioid use disorder (OUD). In Switzerland, pharmaceutical heroin (diacetylmorphine, DAM) is available in table...

    Authors: Jean N. Westenberg, Maximilian Meyer, Johannes Strasser, Michael Krausz, Kenneth M. Dürsteler, Luis Falcato and Marc Vogel
    Citation: Addiction Science & Clinical Practice 2023 18:15
  15. Managed alcohol programs aim to reduce health and social harms associated with severe alcohol use disorder. Here, we describe a young man with severe alcohol use disorder enrolled in a managed alcohol program,...

    Authors: Thomas D. Brothers, Alexander Y. Walley, Helen Rivers-Bowerman, Magnus McLeod and Leah Genge
    Citation: Addiction Science & Clinical Practice 2023 18:14
  16. Patients with opioid use disorder (OUD) frequently leave the hospital as patient directed discharges (PDDs) because of untreated withdrawal and pain. Short-acting opioids can complement methadone, buprenorphin...

    Authors: Ashish P. Thakrar, Tanya J. Uritsky, Cara Christopher, Anna Winston, Kaitlin Ronning, Anna Lee Sigueza, Anne Caputo, Rachel McFadden, Jennifer M. Olenik, Jeanmarie Perrone, M. Kit Delgado, Margaret Lowenstein and Peggy Compton
    Citation: Addiction Science & Clinical Practice 2023 18:13
  17. Unhealthy alcohol use (UAU) affects not only the drinking individual, but also significant others (SOs), such as partners and children. Most of the harm to others caused by alcohol can be attributed to common,...

    Authors: Ola Siljeholm and Veronica Ekström
    Citation: Addiction Science & Clinical Practice 2023 18:12
  18. Co-use of stimulants and opioids is rapidly increasing. Randomized clinical trials (RCTs) have established the efficacy of medications for opioid use disorder (MOUD), but stimulant use may decrease the likelih...

    Authors: R. R. Cook, C. Foot, O. A. Arah, K. Humphreys, K. E. Rudolph, S. X. Luo, J. I. Tsui, X. A. Levander and P. T. Korthuis
    Citation: Addiction Science & Clinical Practice 2023 18:11
  19. Many primary care clinicians (PCCs) hold stigma toward people with opioid use disorder (OUD), which may be a barrier to care. Few interventions exist to address PCC stigma toward people with OUD. This study ex...

    Authors: Stephanie A. Hooker, A. Lauren Crain, Amy B. LaFrance, Sheryl Kane, J. Konadu Fokuo, Gavin Bart and Rebecca C. Rossom
    Citation: Addiction Science & Clinical Practice 2023 18:10
  20. Injection drug use-related endocarditis is increasingly common among hospitalized patients in the United States, and associated morbidity and mortality are rising.

    Authors: Hallie Rozansky, Eric Awtry, Zoe M. Weinstein and Alyssa F. Peterkin
    Citation: Addiction Science & Clinical Practice 2023 18:9
  21. Hospitalizations for severe injection drug use-related infections (SIRIs) are characterized by high costs, frequent patient-directed discharge, and high readmission rates. Beyond the health system impacts, the...

    Authors: Belén Hervera, Grace Seo, Tyler S. Bartholomew, Teresa A. Chueng, Edward Suarez, David W. Forrest, Salma Hernandez, Allan E. Rodriguez, Hansel E. Tookes, Susanne Doblecki-Lewis and David P. Serota
    Citation: Addiction Science & Clinical Practice 2023 18:8
  22. Smoking and resulting health problems disproportionately impact low socioeconomic status (SES) individuals. Building resilience presents an approach to ‘closing the gap’. Mindfulness-based interventions and se...

    Authors: Reece De Zylva, Elissa Mortimer, Emma Miller, George Tsourtos, Sharon Lawn, Carlene Wilson, Jonathan Karnon, Richard Woodman and Paul Ward
    Citation: Addiction Science & Clinical Practice 2023 18:7
  23. Identifying patients in primary care services with opioid use disorder and co-occurring mental health disorders is critical to providing treatment. Objectives of this study were to (1) assess the feasibility o...

    Authors: Cristina Murray-Krezan, Alex Dopp, Lina Tarhuni, Mary D. Carmody, Kirsten Becker, Jessica Anderson, Miriam Komaromy, Lisa S. Meredith, Katherine E. Watkins, Katherine Wagner and Kimberly Page
    Citation: Addiction Science & Clinical Practice 2023 18:6
  24. This study examines the impact of the COVID-19 pandemic on work satisfaction, work-related stress, and perceived work quality among substance use treatment providers to better understand challenges faced among...

    Authors: Andrea Fentem, Raven Riordan, Christine Doroshenko, Xiao Li, Erin Kasson, Devin Banks, Rachel P. Winograd and Patricia Cavazos-Rehg
    Citation: Addiction Science & Clinical Practice 2023 18:5
  25. Problematic substance use and Substance Use Disorders (SUD) are common in all layers of the population. Several studies suggest higher prevalence rates of problematic substance use among physicians compared to...

    Authors: Pauline Geuijen, Arnt Schellekens, Aart Schene and Femke Atsma
    Citation: Addiction Science & Clinical Practice 2023 18:4
  26. Women who use drugs face sexism and intersectional stigma that influence their drug use experiences and treatment needs. There is a need to build the capacity of addiction medicine specialists who can deliver ...

    Authors: Jordana Laks, Alexander Y. Walley, Sarah M. Bagley, Cecily M. Barber, Jessie M. Gaeta, Linda A. Neville, Alyssa F. Peterkin, Emily Rosenthal, Kelley A. Saia, Zoe M. Weinstein and Miriam T. H. Harris
    Citation: Addiction Science & Clinical Practice 2023 18:3
  27. Among people who inject drugs (PWID), obtaining syringes via syringe services programs (SSPs) and pharmacies reduces injection sharing practices associated with hepatitis C virus (HCV). Whether indirect use of...

    Authors: Eric Romo, Abby E. Rudolph, Thomas J. Stopka, Bo Wang, Bill M. Jesdale and Peter D. Friedmann
    Citation: Addiction Science & Clinical Practice 2023 18:2
  28. Substance use among youth is a longstanding global health concern that has dramatically risen in the era of highly toxic and unregulated drugs, including opioids. It is crucial to ensure that youth using unreg...

    Authors: Kirsten Marchand, Roxanne Turuba, Christina Katan, Oonagh Fogarty, Jill Fairbank, Corinne Tallon, Steve Mathias and Skye Barbic
    Citation: Addiction Science & Clinical Practice 2023 18:1
  29. The COVID-19 pandemic and consequent public health response may have undermined key responses to the protracted drug poisoning crisis, including reduced access to opioid agonist therapy (OAT) among people with...

    Authors: Soroush Moallef, Kora DeBeck, Nadia Fairbairn, Zishan Cui, Rupinder Brar, Dean Wilson, Cheyenne Johnson, M.-J. Milloy and Kanna Hayashi
    Citation: Addiction Science & Clinical Practice 2022 17:73
  30. Medication for opioid use disorder (MOUD) includes administering medications such as buprenorphine or methadone, often with mental health services. MOUD has been shown to significantly improve outcomes and suc...

    Authors: Treah Haggerty, Nicholas A. Turiano, Tyra Turner, Patricia Dekeseredy and Cara L. Sedney
    Citation: Addiction Science & Clinical Practice 2022 17:72
  31. Assessing the experiences of individuals on methadone treatment is essential to help evaluate the treatment program’s effectiveness. This study aimed to explore the experiences of patients receiving methadone ...

    Authors: Sarah Kanana Kiburi, Jackline Mwangi and Geoffrey Maina
    Citation: Addiction Science & Clinical Practice 2022 17:71
  32. Despite their crucial role in bridging science and practice, not much is known about counselors offering treatment for Problem Gambling (PG). This study maps current treatment, the type of change techniques th...

    Authors: Viktor Månsson, Eva Samuelsson, Anne H. Berman and Anders Nilsson
    Citation: Addiction Science & Clinical Practice 2022 17:70
  33. This manuscript is the product of the authors’ discussions, literature overview, and consultation with experts in the field, and identifies important gaps in the evidence base for substance use disorder (SUD) ...

    Authors: Nickolas D. Zaller, Margaret M. Gorvine, Jon Ross, Shannon Gwin Mitchell, Faye S. Taxman and David Farabee
    Citation: Addiction Science & Clinical Practice 2022 17:69
  34. Opioid use disorder (OUD) as a common drug use disorder can affect public health issues, including the COVID-19 pandemic, in which patients with OUD may have higher risk of infection and severe disease. This s...

    Authors: Amir Hossein Behnoush, Elham Bazmi, Mehdi Forouzesh and Behnam Behnoush
    Citation: Addiction Science & Clinical Practice 2022 17:68
  35. People who use drugs (PWUD) are at high risk for hepatitis C virus (HCV) infection and its complications. Given the high prevalence rate of HCV in PWUD, the World Health Organization (WHO) emphasizes PWUD as a...

    Authors: Daan W. Von den Hoff, Floor A. C. Berden, Joost P. H. Drenth and Arnt F. A. Schellekens
    Citation: Addiction Science & Clinical Practice 2022 17:67
  36. Approximately 80% of people with a substance use disorder (SUD) are smokers. Starting SUD treatment offers the opportunity to also quit smoking. The ACT-ATAC project aims to identify the predictors associated ...

    Authors: Ariadna Feliu, Esteve Fernández, Yolanda Castellano, Marta Enríquez, Judith Saura, Carmen Cabezas, Joan Colom, Josep M. Suelves, Margarida Pla, Mar Parejo, Sílvia Mondon, Pablo Barrio, Magalí Andreu, Antonia Raich, Jordi Bernabeu, Jordi Vilaplana…
    Citation: Addiction Science & Clinical Practice 2022 17:66
  37. Efficient and linguistically appropriate instruments are needed to assess response to addiction treatment, including severity of addiction/mental health status. This is critical for Russian-speaking persons in...

    Authors: Lynn M. Madden, Scott O. Farnum, Daniel J. Bromberg, Declan T. Barry, Alyona Mazhnaya, Tetiana Fomenko, Anna Meteliuk, Ruthanne Marcus, Julia Rozanova, Iurii Poklad, Sergii Dvoriak and Frederick L. Altice
    Citation: Addiction Science & Clinical Practice 2022 17:65
  38. Alcohol use disorder (AUD) accounts for millions of acute care encounters annually in the United States. Hospitalization represents a vital opportunity to intervene pharmacologically, but low medication adhere...

    Authors: Dale Terasaki, Ryan Loh, Anastasia Cornell, Julie Taub and Christian Thurstone
    Citation: Addiction Science & Clinical Practice 2022 17:64
  39. Despite the proven efficacy of medications for opioid use disorder (MOUD) and recent reduction in barriers to prescribers, numerous obstacles exist for patients seeking MOUD. Prior studies have used telephone ...

    Authors: Alina Syros, Maria G. Rodriguez, Andrew C. Rennick, Grace A. Dima, Alexander R. Gibstein, Lauren de la Parte, Matthew G. Hermenau, Katrina J. Ciraldo, Teresa A. Chueng, Hansel E. Tookes, Tyler S. Bartholomew and David P. Serota
    Citation: Addiction Science & Clinical Practice 2022 17:63
  40. With advances in antiretroviral therapy, people with HIV (PWH) are living longer and are less likely to die from AIDS-related complications. Yet, prior research has shown that smoking is often not addressed in...

    Authors: Brandon T. Sanford, Benjamin A. Toll, Allison Ross Eckard, Katherine R. Sterba, K. Michael Cummings, Nathaniel L. Baker and Alana M. Rojewski
    Citation: Addiction Science & Clinical Practice 2022 17:61
  41. Medication for opioid use disorder (MOUD) reduces mortality, but few patients access MOUD. At a Federally Qualified Health Center (FQHC), we implemented a low barrier model of MOUD, including same-day MOUD ini...

    Authors: Jamie Carter, Zhen Li, Hillary Chen, Melissa Greiner, Christopher Bush, Debanjan Bhattacharya, Stephanie Poley, Nidhi Sachdeva, Jane Carolyn Crowder and Jacob Feigal
    Citation: Addiction Science & Clinical Practice 2022 17:60
  42. In recent years, pediatric emergency departments (PED) have seen an increase in presentations related to substance use among their adolescent patient population. We aimed to examine pediatric emergency medicin...

    Authors: Ariel M. Hoch, Samantha F. Schoenberger, Tehnaz P. Boyle, Scott E. Hadland, Mam Jarra Gai and Sarah M. Bagley
    Citation: Addiction Science & Clinical Practice 2022 17:59
  43. Injection drug use (IDU) remains the strongest risk factor for hepatitis C virus (HCV) in the United States. HCV rates are increasing in rural areas among young adult people who inject drugs (PWID). People wit...

    Authors: Akash Gupta, Fatma M. Shebl, Yao Tong, Katherine Wagner, Ingrid V. Bassett, Kimberly Page and Erin L. Winstanley
    Citation: Addiction Science & Clinical Practice 2022 17:58
  44. Hospitalizations involving opioid use disorder (OUD) have been increasing among Medicare beneficiaries of all ages. With rising OUD-related acute care use comes the need to understand where post-acute care is ...

    Authors: Patience Moyo, Melissa Eliot, Asghar Shah, Kimberly Goodyear, Eric Jutkowitz, Kali Thomas and Andrew R. Zullo
    Citation: Addiction Science & Clinical Practice 2022 17:57
  45. Up to 95% of pregnant women with alcohol and other drug (AOD) problems also smoke tobacco. Challenging psychosocial circumstances and a lack of targeted tobacco interventions contribute to low rates of prenata...

    Authors: Melissa A. Jackson, Penny Buykx, Amanda L. Brown, Amanda L. Baker, Adrian J. Dunlop and Gillian S. Gould
    Citation: Addiction Science & Clinical Practice 2022 17:56
  46. Novel buprenorphine dosing strategies have emerged with an aim to transition patients from opioid agonists to buprenorphine without prerequisite opioid withdrawal. We applied a configurational approach to a su...

    Authors: Adams K. K., Miech E. J. and Sobieraj D. M.
    Citation: Addiction Science & Clinical Practice 2022 17:55
  47. Alcohol consumption is a major public health challenge; the majority of employees consume alcohol regularly and a considerable proportion of employees can be characterized as risky drinkers in need of interven...

    Authors: Mikkel Magnus Thørrisen, Talieh Sadeghi, Tore Bonsaksen, Ian D. Graham and Randi Wågø Aas
    Citation: Addiction Science & Clinical Practice 2022 17:54
  48. Coupling social network visualizations with Motivational Interviewing in substance use interventions has been shown to be acceptable and feasible in several pilot tests, and has been associated with changes in...

    Authors: David P. Kennedy, Elizabeth J. D’Amico, Ryan A. Brown, Alina I. Palimaru, Daniel L. Dickerson, Carrie L. Johnson and Anthony Lopez
    Citation: Addiction Science & Clinical Practice 2022 17:53

Affiliated with

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 3.7
    5-year Journal Impact Factor: 4.2
    Source Normalized Impact per Paper (SNIP): 1.062
    SCImago Journal Rank (SJR): 1.307

    Speed 2023
    Submission to first editorial decision (median days): 28
    Submission to acceptance (median days): 202

    Usage 2023
    Downloads: 755,413
    Altmetric mentions: 622

Archival content

Addiction Science & Clinical Practice was formerly published by NIDA and previous issues of the journal can be viewed here.